Cookies on this site

The largest multiparameter immunoprofiling study in cancer to date has suggested an underappreciated role of a subset of immune cells in determining the risk of bowel cancer relapse after surgery.

Colorectal cancer is the third most common cancer globally, with nearly 2 million cases yearly. About 75% are detected in the early stages and treated with surgery and chemotherapy. Scientists are searching for markers to predict risk and new treatments. In this study, researchers looked at markers in colorectal cancers from large clinical trials to understand their predictive significance.

Researchers looked at the cases from the SCOT trial and the QUASAR 2 trial, both of which were led or supported by the University of Oxford. The main goal of the study was to see whether tumour infiltration by immune cells predicted whether colorectal cancer recurred after initial treatment. 

By looking at multiple immune cell types in more than 3,000 tumours using an AI-based method, the researchers found as expected, tumour infiltration by cytotoxic (CD8) T cells was associated with better outcome. Unexpectedly, they also found that tumour infiltration by regulatory (FoxP3) T cells also predicted better outcome, a result which contrasting with other cancers where these cells confer worse prognosis. Quantification of both cell types improved on the value of either alone for prediction of relapse and may help personalise treatment for patients in the future.

Read the full story on the NDM website. 

Read the paper in The Lancet Oncology.

Similar stories

ARIA gives major boost to Oxford researchers using AI scientists to accelerate cancer vaccine discovery and development

The Advanced Research + Invention Agency (ARIA) has today announced that it is committing an additional £8m of funding to the pioneering UK Cancer Vaccine AI Scientist & Supercomputing Project at the University of Oxford. The funding will enable the research team to extend its AI cancer immunology platform towards patients, bringing together human oncology experts, AI models of tumour-immune recognition, automated laboratory experimentation, Sovereign UK AI supercomputing, personalised vaccine manufacturing and clinical testing.

New review highlights advances and challenges in studying antigen-specific T cells

A new review published in Nature Reviews Immunology by Professor Tao Dong's group at the CAMS Oxford Institute and the MRC Translational Immune Discovery Unit highlights recent advances and remaining challenges in studying antigen-specific T cells - rare immune cells that recognise viruses, bacteria, tumours and self-antigens, and play central roles in protective immunity and autoimmune disease.

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Decades old puzzle solved as scientists uncover cause of inflammatory bowel disease

Scientists have identified the missing link between a long-known genetic signal in inflammatory bowel disease and a damaging immune response that switches off the body’s natural control of inflammation - opening the door to faster diagnosis and targeted treatment.

Oxford Population Health researchers to tackle one of cancer’s toughest challenges

Oxford researchers join $25m international effort to uncover immune mechanisms that protect certain people from cancer.

New Oxford-led trial explores if the immune system can be trained to control HIV

Can the immune system be trained to control HIV without continuous medication? A new Oxford-led clinical trial is exploring whether immune-based strategies could support longer-term viral control after stopping antiretroviral therapy.

Similar stories

ARIA gives major boost to Oxford researchers using AI scientists to accelerate cancer vaccine discovery and development

The Advanced Research + Invention Agency (ARIA) has today announced that it is committing an additional £8m of funding to the pioneering UK Cancer Vaccine AI Scientist & Supercomputing Project at the University of Oxford. The funding will enable the research team to extend its AI cancer immunology platform towards patients, bringing together human oncology experts, AI models of tumour-immune recognition, automated laboratory experimentation, Sovereign UK AI supercomputing, personalised vaccine manufacturing and clinical testing.

New review highlights advances and challenges in studying antigen-specific T cells

A new review published in Nature Reviews Immunology by Professor Tao Dong's group at the CAMS Oxford Institute and the MRC Translational Immune Discovery Unit highlights recent advances and remaining challenges in studying antigen-specific T cells - rare immune cells that recognise viruses, bacteria, tumours and self-antigens, and play central roles in protective immunity and autoimmune disease.

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Decades old puzzle solved as scientists uncover cause of inflammatory bowel disease

Scientists have identified the missing link between a long-known genetic signal in inflammatory bowel disease and a damaging immune response that switches off the body’s natural control of inflammation - opening the door to faster diagnosis and targeted treatment.

Oxford Population Health researchers to tackle one of cancer’s toughest challenges

Oxford researchers join $25m international effort to uncover immune mechanisms that protect certain people from cancer.

New Oxford-led trial explores if the immune system can be trained to control HIV

Can the immune system be trained to control HIV without continuous medication? A new Oxford-led clinical trial is exploring whether immune-based strategies could support longer-term viral control after stopping antiretroviral therapy.